Abstract
Background
In 2003, for the first time, US breast cancer incidence rates have fallen. Experts argue whether this is due to the reduced uptake of screening mammography or to lower use of Hormone Replacement Therapy (HRT). This study aims to disentangle the respective impact of screening and HRT on age-incidence rates and histology of breast cancer, by comparing two populations with comparably high levels of screening mammography, but with different prevalence of HRT.
Methods
We included all invasive breast cancers recorded at the Geneva cancer registry (n = 4,909) and the Netherlands Cancer Registry (n = 152,428) between 1989–2003. We compared age-specific incidence rates and trends in histological subtyping between the two populations.
Results
Between 1989–1991, incidence rates increased with age in both populations. In 2001–2003, women aged 60–64 years showed highest incidence rates in Geneva, while in the Netherlands incidence rates continued to increase with age. The annual increase in ductal cancer incidence was similar in the Netherlands (2.3%) and Geneva (2.5%), but the annual increase in lobular cancer was sharper in Geneva (10%) than in the Netherlands (5%).
Conclusion
The sharp differences in age distribution and histological subtyping of breast cancer between two European populations are not attributable to screening, since both populations have a high uptake of mammography screening. Since the prevalence of HRT use is very high in Geneva and rather low in the Netherlands, HRT may explain these discrepancies. However, other etiological factors and differences in histological assessment may also have played a role.
Similar content being viewed by others
References
Ravdin PA, Cronin KA, Howlander N et al (2006) A sharp decrease in breast cancer incidence in the United States in 2003. Breast Cancer Res Treatm 100:S6–S7
Gøtzsche PC, Olsen O (2000) Is screening for breast cancer with mammography justifiable? Lancet 355:129–134
Olsen O, Gøtzsche PC (2001) Systematic review of screening for breast cancer with mammography. The Lancet Publishing Group, London, UK
Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333
Beral V, Million Women Study Collaborators 2003 Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427
Jonsson H, Johansson R, Lenner P (2005) Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer 117:842–847
Zahl PH, Strand BH, Maehlen J (2004) Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 328:921–924
Otto SJ, Fracheboud J, Looman CW et al (2003) Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 361:1411–1417
Bouchardy C, Morabia A, Verkooijen HM et al (2006) Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. BMC Cancer 6:78
Prehn A, Clarke C, Topol B et al (2002) Increase in breast cancer incidence in middle-aged women during the 1990s. Ann Epidemiol 12:476–481
Fuglede N, Langballe O, Svendsen AL et al (2006) Development in incidence of breast cancer in non-screened danish women, 1973–2002–a population-based study. Int J Cancer 118:2366–2369
Hemminki K, Rawal R, Bermejo JL (2004) Mammographic screening is dramatically changing age-incidence data for breast cancer. J Clin Oncol 22:4652–4653
Hemminki K, Bermejo JL (2005) Effects of screening for breast cancer on its age-incidence relationships and familial risk. Int J Cancer 117:145–149
Li CI, Anderson BO, Porter P et al (2000) Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 88:2561–2569
Verkooijen HM, Fioretta G, Vlastos G et al (2003) Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 104:778–781
Levi F, Te VC, Randimbison L et al (2003) Increase in lobular breast cancer incidence in Switzerland. Int J Cancer 107:164–165
Li CI, Anderson BO, Daling JR et al. (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289:1421–1424
Li CI, Malone KE, Porter PL et al (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289:3254–3263
Daling JR, Malone KE, Doody DR et al (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95:2455–2464
Tjonneland A, Christensen J, Thomsen BL et al (2004) Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100:2328–2337
Bouchardy C (1997) Switzerland, Geneva. In: Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (eds) Cancer incidence in five continents. Vol. VII. International Agency for Research on Cancer, Lyon
Chamot E, Charvet AI, Perneger TV (2007) Who gets screened, and where: a comparison of organised and opportunistic mammography screening in Geneva, Switzerland. Eur J Cancer 43:576–584
van Duijnhoven FJ, Van Gils CH, Bezemer ID et al (2006) Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997. Maturitas 53:462–475
Schaad MA, Bonjour JP, Rizzoli R (2000) Evaluation of hormone replacement therapy use by the sales figures. Maturitas 34:185–191
Morabia A, Costanza MC (2006) Recent reversal of trends in hormone therapy use in a European population. Menopause 13:111–115
World Health Organization (1976) ICD-O International classification of diseases for oncology. Geneva
GLIM 4 the statistical system for generalized linear interactive modelling [computer program]. (1993) Oxford University Press, Oxford
Bakken K, Lund E, Eggen AE (2005) The impact of hormone replacement therapy on the incidence of breast cancer in Norway. J Clin Oncol 23:3636–3637
Li CI, Weiss NS, Stanford JL et al (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88:2570–2577
Martinez V, Azzopardi JG (1979) Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 3:467–488
Fechner RE (1975) Histologic variants of infiltrating lobular carcinoma of the breast. Hum Pathol 6:373–378
Acknowledgements
Dr. H. M. Verkooijen was financially supported by a PROSPER Grant (3233-069350) from the Swiss National Science Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Verkooijen, H.M., Koot, V.C.M., Fioretta, G. et al. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 107, 389–395 (2008). https://doi.org/10.1007/s10549-007-9554-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-007-9554-3